Business Context and Reporting Period
Company: Owens & Minor, Inc. (Note: Input metadata referenced "Accendra Health Inc," but the filing text is for Owens & Minor, Inc.)
Filing Type: Form 10-K (Annual Report)
Period: Year ended December 31, 2024
Overview: A global healthcare solutions company operating in two segments: Products & Healthcare Services (medical distribution and manufacturing) and Patient Direct (home healthcare equipment and services). The company serves customers in approximately 80 countries.
Key Financial Metrics
| Metric | 2024 | 2023 | Change |
|---|---|---|---|
| Net Revenue | $10.70 billion | $10.33 billion | +3.6% |
| Net (Loss) Income | $(362.7) million | $(41.3) million | Worsened |
| Diluted EPS | $(4.73) | $(0.54) | Worsened |
| Operating (Loss) Income | $(207.8) million | $104.5 million | Declined |
| Segment Income (Products & Healthcare Services) | $53.0 million | $57.8 million | -8.3% |
| Segment Income (Patient Direct) | $260.2 million | $246.9 million | +5.4% |
| Total Debt | $1.85 billion | $2.10 billion | -11.6% |
| Cash and Cash Equivalents | $49.4 million | $243.0 million | -79.7% |
| Operating Cash Flow | $161.5 million | $740.7 million | Significant Decline |
| Days Sales Outstanding (DSO) | 23.3 days | 20.5 days | Increased |
Material Changes vs. Prior Period
- Goodwill Impairment: Recorded a non-cash goodwill impairment charge of $307 million in the Apria reporting unit (Patient Direct segment) during Q4 2024. This was driven by a decline in stock price, rising interest rates, and anticipated changes in capitated contract pricing.
- Tax Charge: Incurred a one-time income tax charge of $19 million due to the remeasurement of an uncertain tax position related to past transfer pricing methodology.
- Legal Settlements: Recorded $17 million in legal settlements primarily related to compensation and wage/hour disputes.
- Exit and Realignment: Incurred $110 million in exit and realignment charges, primarily for the 2023-2024 Operating Model Realignment Program and IT strategic initiatives.
- Revenue Growth: Patient Direct revenue grew 5.0% driven by growth in diabetes and sleep supplies. Products & Healthcare Services revenue grew 3.1%, offset by competitive pricing pressures in gloves.
- Philips Respironics Recall: Received a $5.4 million benefit from an agreement with Philips regarding previously recalled equipment.
Guidance, Outlook, and Strategic Developments
- Potential Sale of Segment: On February 28, 2025, the company announced it is actively engaged in discussions regarding the potential sale of its Products & Healthcare Services segment. There is no set timetable, and completion is not assured.
- Rotech Acquisition: Entered into an agreement on July 22, 2024, to acquire Rotech Healthcare Holdings Inc. for approximately $1.36 billion in cash (net purchase price ~$1.32 billion). The transaction is expected to close in the first half of 2025 and will be funded by cash and incremental borrowings. A termination fee of $70 million applies if the company terminates the contract.
- Share Repurchase: On February 26, 2025, the Board authorized a new share repurchase program of up to $100 million over the next 24 months.
- Liquidity: The company maintains a $450 million Revolving Credit Agreement with $419 million available as of year-end. It also utilizes a Receivables Sale Program with a $450 million capacity.
- Risks: Key risks include the uncertainty of the segment sale and Rotech acquisition, regulatory scrutiny (including a Corporate Integrity Agreement with Apria), and exposure to commodity price fluctuations (polypropylene, nitrile).
Investor Verification Checklist
- Goodwill Impairment Sensitivity: Verify the assumptions used in the Apria impairment test, specifically the discount rate and terminal growth rate, as a 100 basis point increase in the discount rate would have increased the charge by ~$45 million.
- Segment Sale Progress: Monitor for updates on the potential sale of the Products & Healthcare Services segment, including any definitive agreements or termination of discussions.
- Rotech Financing: Confirm the final terms of the incremental borrowings required to fund the Rotech acquisition and the impact on leverage ratios.
- Tax Liability: Review the status of the $43 million owed related to the IRS Notice of Proposed Adjustment (NOPA) matter and the timing of final settlement.
- Working Capital Trends: Analyze the increase in DSO (from 20.5 to 23.3 days) and the significant drop in operating cash flow to ensure collection trends are stabilizing.